¹⁸F-Fluorination Reactions and Optimizations using a Parallel Synthesis Reactor




HELMHOLTZ ZENTRUM **DRESDEN** ROSSENDORF

A. Craig¹, K. Kopka^{1,2}, S. Stadlbauer¹, J. Pietzsch^{1,2}, M. Laube¹

¹ Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany; ² Faculty of Chemistry and Food Chemistry, School of Science, Technische Universität Dresden, Dresden, Germany

Objectives




- Preparation of ¹⁸F-labeled compounds requires time-sensitive processes including azeotropic drying, ¹⁸F-fluorination, deprotection, purification and formulation.
- Recent advances in late-stage ¹⁸F-fluorination approaches, such as coppermediated radiofluorination (CMRF) chemistry, have paved the way for accelerated development of structurally-diverse PET tracers.^{1,2}
- CMRF reactions require particular attention with respect to reaction optimization in manual radiosyntheses.³

Figure 1: Nevolab's Xelsius[®] multi-vessel device (left) and its implementation into radionuclide hood (right)

• Herein, the potential of a Xelsius® parallel reactor screening device in manual radiosyntheses and CMRF reaction optimizations is disclosed.

AIM OF THIS WORK: Radiolabeling optimization using Nevolab's Xelsius parallel synthesizer for PET tracer development


Methods




- Figure 2: Radiofluorination reactions towards [¹⁸F]**2** and [¹⁸F]**4**
- Two approaches were tested: 1) Radiosynthesis of an ¹⁸F-labeled COX-2 inhibitor [¹⁸F]**2**,⁴ and 2) A parallel optimization of CMRF on model compound **3** at different temperatures (Figure 2).
- Preparation of [¹⁸F]2 commenced with azeotropic drying at 95 °C, ¹⁸F-fluorination at 140 °C, HPLC and SPE purification, and concentration of the final compound at 70 °C. For the radiofluorination optimization of $[^{18}F]$ **4**; dried $[^{18}F]$ fluoride/ Et₄NHCO₃ was reacted with precursor **3** in DMA/*n*-BuOH (4:1) under CMRF conditions in parallel with stirring for 5-20 min at 90 °C, 100 °C, 110 °C and 120 °C, respectively.
- The radiochemical conversion (RCC) values were determined by taking aliquots from the respective vessels at defined intervals and analyzing their contents by radio-UHPLC.



- Radiosyntheses were performed manually using the Xelsius® parallel synthesis reactor (Nevolab, Figure 3) offering ten separately controllable positions to perform reactions between -20 °C and 150 °C.
- Heating steps were performed at separate positions of the device while one position was cooled at -10 °C to trap contaminated distillates.



Results



- For approaches, both the \bullet radiosyntheses were translated to the parallel synthesis reactor.
- The different heating steps in the • multi-step radiosynthesis of [¹⁸F]**2** different performed at were positions in the device without the need to wait between the for single reaction steps temperature equilibration.

Conclusions & Outlook

- ✓ Using a parallel synthesis reactor can facilitate multi-step radiosyntheses and optimizations in radiochemistry taking into consideration the space-saving construction of the device and the ability to investigate different temperature conditions at a time as well as the ability to fastly switch between different temperatures.
- \checkmark The ¹⁸F-labeling results were comparable to previous reports in the literature, and facilitated rapid screening of [¹⁸F]**4** preparation via CMRF.
- \checkmark Notably, for our initial screening only four vessels were
- Radiofluorination rates for [¹⁸F]**4** (Figure 4) at the respective timepoints and temperatures ranged between 44-93% RCC.
- The overall duration for the series of four ¹⁸F-fluorination reactions took 1 hour. The use of a reaction vessel as a cooling trap to facilitate the evaporation of MeOH was carried out upon attachment of a cooler.

simultaneously used; however, it is anticipated that the use of the six additional vessels would further accelerate ¹⁸Ffluorination reaction optimization.

 \checkmark The automation of the radiolabeling screening method would be an outlook of this project.

References

[1] B. D. Zlatopolskiy et al. Chem. Eur. J. 2015, 21, 5972-5979. [2] C. Hoffmann et al. Chem. Eur. J. 2023, 29, e202202965. [3] G. D. Bowden et al. Sci. Rep. 2019, 9, 11370. [4] M. Y. Cortes-Salva et al. Molecules 2018, 23, 2850.

Acknowledgments

NevoLAB GmbH (Maierhöfen, Germany) is greatly acknowledged for providing Xelsius® parallel synthesis reactor as test device and fruitful discussions within this project.

Institute of Radiopharmaceutical Cancer Research Dr. Austin Craig · a.craig@hzdr.de · www.hzdr.de

